Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

512
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
512
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

144
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
144
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

291
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
291
Fats as Energy Storage Molecules01:06

Fats as Energy Storage Molecules

24.7K
Triglycerides are a form of long-term energy storage molecules. They are made of glycerol and three fatty acids. To obtain energy from fat, triglycerides must first be broken down by hydrolysis into their two principal components, fatty acids and glycerol. This process, called lipolysis, takes place in the cytoplasm. The resulting fatty acids are oxidized by β-oxidation into acetyl-CoA, which is used by the Krebs cycle. The glycerol that is released from triglycerides after lipolysis...
24.7K
Lipid Digestion01:06

Lipid Digestion

90.6K
Lipids are large molecules that are generally not water-soluble. Since most of the digestive enzymes in the human body are water-based, there are specific steps the body must take to break down lipids and make them available for use.
90.6K
Lipid Absorption01:24

Lipid Absorption

345
Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
345

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Unintentional overestimation of an expected antihypertensive effect in drug and device trials: mechanisms and solutions.

International journal of cardiology·2014
Same author

Saxagliptin, alogliptin, and cardiovascular outcomes.

The New England journal of medicine·2014
Same author

Quality of care for patients with acute coronary syndromes as a function of hospital revascularization capability: Insights from get with the guidelines-CAD.

Clinical cardiology·2014
Same author

Peripheral artery disease is a coronary heart disease risk equivalent among both men and women: results from a nationwide study.

European journal of preventive cardiology·2014
Same author

Obstructive sleep apnea and diurnal nondipping hemodynamic indices in patients at increased cardiovascular risk.

Journal of hypertension·2013
Same author

The latest research advances in invasive cardiology.

The Journal of invasive cardiology·2013

Related Experiment Video

Updated: May 27, 2025

Assessing Whole-Body Lipid-Handling Capacity in Mice
07:57

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

3.9K

Emerging agents targeting triglycerides.

Yash Prakash1, Deepak L Bhatt2, Waqas A Malick2

  • 1Samuel Bronfman Department of Medicine.

Current Opinion in Lipidology
|February 18, 2025
PubMed
Summary
This summary is machine-generated.

Emerging therapies targeting triglyceride-rich lipoprotein metabolism offer new hope for managing hypertriglyceridemia (HTG). Apolipoprotein C-III inhibitors, ANGPTL3/4 inhibitors, and FGF21 analogs show promise for diverse HTG patient groups.

Keywords:
angiopoeitin-like proteinsapolipoprotein C-IIIfibroblast growth factor analoghypertriglyceridemialipid metabolism

More Related Videos

Measuring the Rate of Lipolysis in Ex Vivo Murine Adipose Tissue and Primary Preadipocytes Differentiated In Vitro
09:41

Measuring the Rate of Lipolysis in Ex Vivo Murine Adipose Tissue and Primary Preadipocytes Differentiated In Vitro

Published on: March 17, 2023

2.7K
A Fluorescence-based Assay for Characterization and Quantification of Lipid Droplet Formation in Human Intestinal Organoids
10:12

A Fluorescence-based Assay for Characterization and Quantification of Lipid Droplet Formation in Human Intestinal Organoids

Published on: October 13, 2019

9.0K

Related Experiment Videos

Last Updated: May 27, 2025

Assessing Whole-Body Lipid-Handling Capacity in Mice
07:57

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

3.9K
Measuring the Rate of Lipolysis in Ex Vivo Murine Adipose Tissue and Primary Preadipocytes Differentiated In Vitro
09:41

Measuring the Rate of Lipolysis in Ex Vivo Murine Adipose Tissue and Primary Preadipocytes Differentiated In Vitro

Published on: March 17, 2023

2.7K
A Fluorescence-based Assay for Characterization and Quantification of Lipid Droplet Formation in Human Intestinal Organoids
10:12

A Fluorescence-based Assay for Characterization and Quantification of Lipid Droplet Formation in Human Intestinal Organoids

Published on: October 13, 2019

9.0K

Area of Science:

  • Biochemistry
  • Metabolic Diseases
  • Pharmacology

Background:

  • Hypertriglyceridemia (HTG) involves defects in triglyceride-rich lipoprotein (TRL) metabolism.
  • HTG increases risks of pancreatitis and atherosclerotic cardiovascular disease.
  • Traditional therapies for HTG have limited efficacy in controlling triglyceride levels and cardiovascular risk.

Purpose of the Study:

  • To review emerging therapies for HTG targeting novel biochemical pathways.
  • To explore novel treatments for triglyceride and TRL metabolism.

Main Methods:

  • Literature review of emerging therapies for HTG.
  • Analysis of novel biochemical pathways and their therapeutic potential.

Main Results:

  • Apolipoprotein C-III inhibitors are effective for severe HTG variants, enhancing TRL metabolism.
  • ANGPTL3/4 inhibitors benefit mixed hyperlipidemia and atherogenic lipoproteins.
  • FGF21 analogs may help HTG patients with insulin resistance, metabolic dysfunction-associated steatotic liver disease, and type 2 diabetes.

Conclusions:

  • HTG is a heterogeneous condition requiring diverse treatment strategies.
  • Apolipoprotein C-III inhibitors, ANGPTL3/4 inhibitors, and FGF21 analogs represent significant advancements.
  • These novel therapies offer improved management options for the full spectrum of HTG.